RxDoctor Payments Data

Domingo Jimenez, MD

Internal Medicine · Binghamton, NYNPI 1699761940

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 53.6% of the total.

$407in general payments, 2019–2025

Across 19 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • Viiv Healthcare Company$98
  • E.r. Squibb & Sons, L.L.C.$36
  • Merck$21
  • Sanofi-aventis U.S. LLC$18
  • Braeburn Inc.$15

What the payments were for

  • Food & beverage$407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$407 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$68,311
Medicare patients
335
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin181$258,210
EliquisApixaban149$154,757
BiktarvyBictegrav/Emtricit/Tenofov Ala28$122,057
TrulicityDulaglutide98$103,857
OzempicSemaglutide101$97,016
TradjentaLinagliptin71$77,266
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$77,153
FarxigaDapagliflozin Propanediol55$72,571
XareltoRivaroxaban52$69,992
MounjaroTirzepatide52$64,661
PrezcobixDarunavir/Cobicistat22$62,247
NuplazidPimavanserin Tartrate13$61,039
JanumetSitagliptin Phos/Metformin Hcl40$52,572
EntrestoSacubitril/Valsartan28$33,420
JentaduetoLinagliptin/Metformin Hcl21$29,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Isentress$21$74,73152 claims
Viiv Healthcare CompanyTivicay$98$28,93113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →